Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P56851 (
epididymal
)
11,273
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We previously investigated whether inhibition of AMP-metabolizing enzymes could enhance AMP-activated protein kinase (AMPK) activation in skeletal muscle for the treatment of type 2 diabetes. Soluble 5'-nucleotidase II (
NT5C2
) hydrolyzes IMP and its inhibition could potentially lead to a rise in AMP to activate AMPK. In the present study, we investigated effects of
NT5C2
deletion in mice fed a normal-chow diet (NCD) or a high-fat diet (HFD). On a NCD,
NT5C2
deletion did not result in any striking metabolic phenotype. On a HFD however,
NT5C2
knockout (
NT5C2
-/-
) mice displayed reduced body/fat weight gain, improved glucose tolerance, reduced plasma insulin, triglyceride and uric acid levels compared with wild-type (WT) mice. There was a tendency towards smaller and fewer adipocytes in
epididymal
fat from
NT5C2
-/-
mice compared to WT mice, consistent with a reduction in triglyceride content. Differences in fat mass under HFD could not be explained by changes in mRNA expression profiles of
epididymal
fat from WT versus
NT5C2
-/-
mice. However, rates of lipolysis tended to increase in
epididymal
fat pads from
NT5C2
-/-
versus WT mice, which might explain reduced fat mass. In incubated skeletal muscles, insulin-stimulated glucose uptake and associated signalling were enhanced in
NT5C2
-/-
versus WT mice on HFD, which might contribute towards improved glycemic control. In summary,
NT5C2
deletion in mice protects against HFD-induced weight gain, adiposity, insulin resistance and associated hyperglycemia.
...
PMID:Genetic deletion of soluble 5'-nucleotidase II reduces body weight gain and insulin resistance induced by a high-fat diet. 3080 94